Video Highlights from Targeting Metabesity Conference 2021

Major diseases including cardiovascular, diabetes, cancer, and the aging process itself have common metabolic roots and may respond to shared solutions. Metabesity is the name for this constellation of conditions.

On October 11-14, 2021 I was a speaker at?Targeting Metabesity 2021?with 80 thought leaders from multiple disciplines. This is one of the most important conferences of the year with a staggering lineup of speakers. We discussed some of the most critical issues in healthcare including key questions that will impact the future of aging. The conference was hosted by Kitalys Institute which was founded by Alexander Fleming, MD, the person who coined the term Metabesity. I was on Nir Barzilai's Longevity Developments Roundtable discussing funding, growing ecosystems, and emerging hubs. I watched many of the discussions in real time and some of the recorded sessions after the conference. The following are videos that I selected with highlights from the week.

Video Highlights from Targeting Metabesity 2021

Fireside Chat with Eric Topol, MD - What will it take to increase healthy longevity?

Participants: Eric Topol, MD, Founder and Director, Scripps Research Translational Institute, Alexander Fleming, MD, Founder and Executive Chairman of Kinexum, Lawrence Steinman, MD, Professor at Stanford University

Scientific Advances in Geroscience - What recent and imminent scientific breakthroughs should we all know about?

Participants: Nir Barzilai, MD, Ana Marie Cuervo,?PhD, Vadim Gladyshev, PhD, Brian Kennedy, PhD, Joan Mannick, MD, Vittorio Sebastiano

Metabolic Roots of Metabesity - What are the metabolic, inflammatory, and other pathways that stand out as promising targets for interventions to mofify the aging process and age-related diseases?

Participants: Jay Skyler, MD, MACP, Ralph DeFronzo, MD, Guido Kroemer, MD, PhD, Laura Niedernhofer, MD, PhD,?Gerald Shulman, MD, PhD, Hazel Szeto, MD, PhD

Longevity Initiatives and Ecosystems - Have we reached a tipping point in the global longevity ecosystem? What are the major non-technical developments including funding, longevity hubs, and initiatives?

Participants: Nir Barzilai, MD, Margaretta Colangelo, Sergey Young,?Victor Dzau, MD, Matt Kaeberlein, PhD, Mehmood Khan, MD

Biomarkers of Aging - How can we find reliable biomarkers of aging that predict and demonstrate effective interventions? What should a biological clock measure?

Participants: Morgan Levine, PhD, Dan Belsky, PhD,Bobby Brooke, Daniel Ives, PhD, Miсhelle Keller, Jamie Justice, PhD, Chris Leptak, MD, PhD, Alex Zhavoronkov, PhD

Targeting Mitochondria - What targets for increasing healthspan do mitochondria offer?

?Participants: Doug Wallace, PhD, Francesca Fieni, PharmD, PhD,? Hazel Szeto, MD, PhD

Establishing Clear Pathways - How do we get evidence in a timely and efficient way to support use of a product aimed at increasing healthspan? What should a phase 3 clinical trial of a healthspan product look like?

Participants: Alexander Fleming, MD, Gordon Cutler, MD, Mark Espeland PhD, David Fox, JD, Stephen Grossman, JD, Brian Harvey, MD, PhD, Theresa Kehoe, MD, Peter Libby, MD, Joan Mannick, MD, Line Jee Hartmann Rasmussen, PhD, Ed Saltzman, Jeffrey Siegel, MD, Sue-Jane Wang, PhD.

Highlights From Emerging Company Showcase

On Day 4 of the conference, 20 companies in the healthy longevity space were featured in the Emerging Company Showcase.?Life Biosciences’ CEO Jerry McLaughlin, Amazentis Life Sciences’ CMO Anurag Singh, MD, PhD, and Juvena Therapeutics’ Co-Founder and CEO Hanadie Yousef gave their pitches, to name a few.?A video of one of the presentations, by Doug Ethell, PhD, Founder & CEO, Leucadia Therapeutics, is provided below.??

Leucadia Therapeutics has developed a non-invasive method to predict who will get Alzheimer’s disease and when—and a therapeutic device that could prevent the disease from occurring at all. Seven years ago, Leucadia's founder Doug Ethell, PhD, published a hypothesis for Alzheimer’s disease that focused on a drainage system the brain uses to clear away toxic metabolites. The premise is that fixing that drainage system could prevent the disease. Leucadia recently published compelling evidence of the relationship between cribriform plate and Alzheimer’s disease.

Subscribe and Comment

I'm interested in your feedback - please leave your comments. To subscribe please click subscribe at the top of this article.

This article was written by?Margaretta Colangelo. Margaretta is Co-founder and CEO of?Jthereum, an enterprise Blockchain technology company. She is the host of AI Time Journal's AI in Healthcare Podcast. Margaretta serves on the advisory boards of the AI Precision Health Institute at the University of Hawaii Cancer Center, Kitalys Institute, NaNotics, Leucadia Therapeutics, Foresight Institute Health Extension Accelerator, serves on the expert committee for the world’s first Global Longevity Finance Hub in India, and is a member of the Digital Health Innovation Research Group at Muhimbili University of Health and Allied Sciences in Dar es Salaam, Tanzania.?She is based in San Francisco.?@realmargaretta